Active Ingredient History
Vortioxetine is an antidepressant for the treatment of major depressive disorder. Vortioxetine’s mechanism of action is not fully understood. Vortioxetine binds with high affinity to the serotonin transporter and its antidepressant actions are believed to be secondary to enhancing serotonin in the central nervous system through inhibition of reuptake. Vortioxetine also displays binding affinities to other serotonin (5-HT) receptors, including 5-HT3, 5-HT1A, and 5-HT7. Due to multimodal neurotransmitter enhancer profile, it has been suggested that it might need lesser receptor occupancy rate for clinical trials than other selective serotonin reuptake inhibitors and selective norepinephrine reuptake inhibitors. Since vortioxetine is an agonist and antagonist of multiple serotonin receptors, potential interactions may occur with other medications that alter the serotonergic pathways. There is an increased risk of serotonin syndrome when vortioxetine is used in combination with other serotonergic agents. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Alcoholism (Phase 2)
Anxiety Disorders (Phase 4)
Binge-Eating Disorder (Phase 2)
Bipolar Disorder (Phase 4)
Brain Injuries, Traumatic (Phase 3)
Breast Neoplasms (Phase 4)
Burning Mouth Syndrome (Phase 3)
Cannabis (Phase 2/Phase 3)
Cognition Disorders (Phase 4)
Cognitive Dysfunction (Phase 4)
Coronary Artery Disease (Early Phase 1)
COVID-19 (Phase 2)
Dementia (Phase 4)
Depression (Phase 4)
Depressive Disorder, Major (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Drug Therapy (Phase 2/Phase 3)
Healthy Volunteers (Phase 4)
Hoarding Disorder (Phase 3)
Hot Flashes (Phase 4)
Liver Diseases (Phase 1)
Menopause (Phase 4)
Panic Disorder (Phase 4)
Pharmacokinetics (Phase 1)
Phobia, Social (Phase 4)
Pruritus (Phase 1)
Radiation Injuries (Phase 3)
Recurrence (Phase 4)
Schizophrenia (Phase 4)
Signs and Symptoms (Phase 2/Phase 3)
Sleep (Phase 4)
Stress Disorders, Post-Traumatic (Phase 4)
Treatment Outcome (Phase 3)
Vasomotor System (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue